Close Menu

NEW YORK – With a new CEO at the helm, HiberGene is refocusing its efforts toward research and development. The Dublin, Ireland-based firm is using low cost as the rubric in its development of a new point-of-care molecular diagnostics instrument that will be based on its core technologies.

Simona Esposito replaced CEO and co-founder Brendan Farrell, who retired last year, in April, after joining HiberGene as chief commercial officer nine months ago.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Sponsored by
Sophia Genetics

This webinar will discuss how Moffitt Cancer Center has implemented a new capture-based application to accurately assess myeloid malignancies by detecting complex variants in challenging genes in a single experiment.